Global Cardiovascular Drugs Market Research Report 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 104

Report ID: 6151

Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.

The global Cardiovascular Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cardiovascular Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cardiovascular Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Renin-Angiotensin System Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Antihyperlipidemic

Segment by Application
Hypertension
Hyperlipidemia

Table of Contents

Executive Summary
1 Cardiovascular Drugs Market Overview
1.1 Product Overview and Scope of Cardiovascular Drugs
1.2 Cardiovascular Drugs Segment by Type
1.2.1 Global Cardiovascular Drugs Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Renin-Angiotensin System Blockers
1.2.3 Beta Blockers
1.2.4 Diuretics
1.2.5 Anti-Clotting Agents
1.2.6 Antihyperlipidemic
1.3 Cardiovascular Drugs Segment by Application
1.3.1 Cardiovascular Drugs Consumption Comparison by Application (2014-2025)
1.3.2 Hypertension
1.3.3 Hyperlipidemia
1.4 Global Cardiovascular Drugs Market by Region
1.4.1 Global Cardiovascular Drugs Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global Cardiovascular Drugs Market Size
1.5.1 Global Cardiovascular Drugs Revenue (2014-2025)
1.5.2 Global Cardiovascular Drugs Production (2014-2025)

2 Global Cardiovascular Drugs Market Competition by Manufacturers
2.1 Global Cardiovascular Drugs Production Market Share by Manufacturers (2014-2019)
2.2 Global Cardiovascular Drugs Revenue Share by Manufacturers (2014-2019)
2.3 Global Cardiovascular Drugs Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Cardiovascular Drugs Production Sites, Area Served, Product Types
2.5 Cardiovascular Drugs Market Competitive Situation and Trends
2.5.1 Cardiovascular Drugs Market Concentration Rate
2.5.2 Cardiovascular Drugs Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Cardiovascular Drugs Production Market Share by Regions
3.1 Global Cardiovascular Drugs Production Market Share by Regions
3.2 Global Cardiovascular Drugs Revenue Market Share by Regions (2014-2019)
3.3 Global Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Cardiovascular Drugs Production
3.4.1 North America Cardiovascular Drugs Production Growth Rate (2014-2019)
3.4.2 North America Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Cardiovascular Drugs Production
3.5.1 Europe Cardiovascular Drugs Production Growth Rate (2014-2019)
3.5.2 Europe Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Cardiovascular Drugs Production (2014-2019)
3.6.1 China Cardiovascular Drugs Production Growth Rate (2014-2019)
3.6.2 China Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Cardiovascular Drugs Production (2014-2019)
3.7.1 Japan Cardiovascular Drugs Production Growth Rate (2014-2019)
3.7.2 Japan Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Cardiovascular Drugs Consumption by Regions
4.1 Global Cardiovascular Drugs Consumption by Regions
4.2 North America Cardiovascular Drugs Consumption (2014-2019)
4.3 Europe Cardiovascular Drugs Consumption (2014-2019)
4.4 China Cardiovascular Drugs Consumption (2014-2019)
4.5 Japan Cardiovascular Drugs Consumption (2014-2019)

5 Global Cardiovascular Drugs Production, Revenue, Price Trend by Type
5.1 Global Cardiovascular Drugs Production Market Share by Type (2014-2019)
5.2 Global Cardiovascular Drugs Revenue Market Share by Type (2014-2019)
5.3 Global Cardiovascular Drugs Price by Type (2014-2019)
5.4 Global Cardiovascular Drugs Production Growth by Type (2014-2019)

6 Global Cardiovascular Drugs Market Analysis by Applications
6.1 Global Cardiovascular Drugs Consumption Market Share by Application (2014-2019)
6.2 Global Cardiovascular Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Cardiovascular Drugs Business
7.1 Amgen
7.1.1 Amgen Cardiovascular Drugs Production Sites and Area Served
7.1.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.1.3 Amgen Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 AstraZeneca
7.2.1 AstraZeneca Cardiovascular Drugs Production Sites and Area Served
7.2.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.2.3 AstraZeneca Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Bayer
7.3.1 Bayer Cardiovascular Drugs Production Sites and Area Served
7.3.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.3.3 Bayer Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served
7.4 Bristol Myers Squibb and Pfizer
7.4.1 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Production Sites and Area Served
7.4.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.4.4 Main Business and Markets Served
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Cardiovascular Drugs Production Sites and Area Served
7.5.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.5.3 Daiichi Sankyo Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.5.4 Main Business and Markets Served
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Cardiovascular Drugs Production Sites and Area Served
7.6.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.6.3 Johnson & Johnson Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.6.4 Main Business and Markets Served
7.7 Merck & Co.
7.7.1 Merck & Co. Cardiovascular Drugs Production Sites and Area Served
7.7.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.7.3 Merck & Co. Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.7.4 Main Business and Markets Served
7.8 Novartis
7.8.1 Novartis Cardiovascular Drugs Production Sites and Area Served
7.8.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.8.3 Novartis Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.8.4 Main Business and Markets Served
7.9 Pfizer
7.9.1 Pfizer Cardiovascular Drugs Production Sites and Area Served
7.9.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.9.3 Pfizer Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.9.4 Main Business and Markets Served
7.10 Portola
7.10.1 Portola Cardiovascular Drugs Production Sites and Area Served
7.10.2 Cardiovascular Drugs Product Introduction, Application and Specification
7.10.3 Portola Cardiovascular Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.10.4 Main Business and Markets Served
7.11 Sanofi

8 Cardiovascular Drugs Manufacturing Cost Analysis
8.1 Cardiovascular Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Cardiovascular Drugs
8.4 Cardiovascular Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Cardiovascular Drugs Distributors List
9.3 Cardiovascular Drugs Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Cardiovascular Drugs Market Forecast
11.1 Global Cardiovascular Drugs Production, Revenue Forecast
11.1.1 Global Cardiovascular Drugs Production Growth Rate Forecast (2019-2025)
11.1.2 Global Cardiovascular Drugs Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Cardiovascular Drugs Price and Trend Forecast (2019-2025)
11.2 Global Cardiovascular Drugs Production Forecast by Regions (2019-2025)
11.2.1 North America Cardiovascular Drugs Production, Revenue Forecast (2019-2025)
11.2.2 Europe Cardiovascular Drugs Production, Revenue Forecast (2019-2025)
11.2.3 China Cardiovascular Drugs Production, Revenue Forecast (2019-2025)
11.2.4 Japan Cardiovascular Drugs Production, Revenue Forecast (2019-2025)
11.3 Global Cardiovascular Drugs Consumption Forecast by Regions (2019-2025)
11.3.1 North America Cardiovascular Drugs Consumption Forecast (2019-2025)
11.3.2 Europe Cardiovascular Drugs Consumption Forecast (2019-2025)
11.3.3 China Cardiovascular Drugs Consumption Forecast (2019-2025)
11.3.4 Japan Cardiovascular Drugs Consumption Forecast (2019-2025)
11.4 Global Cardiovascular Drugs Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Cardiovascular Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer